Search results for "204"

showing 10 items of 5248 documents

Dairy consumption, plasma metabolites, and risk of type 2 diabetes.

2021

Background Epidemiologic studies have reported a modest inverse association between dairy consumption and the risk of type 2 diabetes (T2D). Whether plasma metabolite profiles associated with dairy consumption reflect this relationship remains unknown. Objectives We aimed to identify the plasma metabolites associated with total and specific dairy consumption, and to evaluate the association between the identified multi-metabolite profiles and T2D. Methods The discovery population included 1833 participants from the Prevencion con Dieta Mediterranea (PREDIMED) trial. The confirmatory cohorts included 1522 PREDIMED participants at year 1 of the trial and 4932 participants from the Nurses' Hea…

0301 basic medicineMalemedicine.medical_specialtyMetabolitePopulationMedicine (miscellaneous)Type 2 diabetes030204 cardiovascular system & hematologycheeseCohort Studiesyogurt03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicineMedicineAnimalsHumansProspective StudieseducationProspective cohort studyDieta mediterraneaAgedmilkprospective cohort studyeducation.field_of_studyNutrition and DieteticsHealth professionalsbusiness.industryEditorialsFeeding BehaviorMiddle Agedmedicine.diseasemetabolomicsPredimed030104 developmental biologyMilkchemistryDiabetes Mellitus Type 2CohortdairyFemaletype 2 diabetesDairy ProductsbusinessThe American journal of clinical nutrition
researchProduct

Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine‐N‐oxide

2018

Aims Trimethylamine-N-oxide (TMAO) is a novel cardiovascular risk marker. We explored the association of commonly used cardiovascular medications with TMAO levels in patients and validated the identified associations in mice. Methods Detailed history of drug treatment was recorded in 300 patients with cardiovascular disease without diabetes in an observational, cross-sectional study. Animal study was performed in CD1 mice. Results Median plasma TMAO (interquartile range) level was 2.144 (1.570-3.104) μmol l-1 . Among nine cardiovascular drug groups, the use of loop diuretics (0.510 ± 0.296 in users vs. 0.336 ± 0.272 in nonusers, P = 0.008) and mineralocorticoid receptor antagonists (0.482 ±…

0301 basic medicineMalemedicine.medical_specialtyOrganic anion transporter 1medicine.drug_classTrimethylamine N-oxide030204 cardiovascular system & hematologyKidneyExcretion03 medical and health scienceschemistry.chemical_compoundMethylaminesMice0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsInternal medicineBlood plasmamedicineAnimalsHumansPharmacology (medical)AgedPharmacologybiologyChemistryArea under the curveFurosemideCardiovascular AgentsHeartOriginal ArticlesLoop diureticMiddle AgedProbenecid030104 developmental biologyEndocrinologyCross-Sectional StudiesLiverCardiovascular Diseasesbiology.proteinFemaleBiomarkersmedicine.drug
researchProduct

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study

2021

Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, …

0301 basic medicineMalemedicine.medical_specialtySettore MED/09 - Medicina Internaadverse effects; myopathy; statin-associated muscle symptoms; statinsstatin-associated muscle symptomsadverse effects; myopathy; statin-associated muscle symptoms; statins.030204 cardiovascular system & hematologystatinsMedication Adherence03 medical and health sciences0302 clinical medicineMuscular DiseasesInternal medicineadverse effectInternal MedicinemedicinePrevalencestatins.Humansstatin‐associated muscle symptomsAdverse effectDechallengeadverse effects; myopathy; statin-associated muscle symptoms; statins; Creatine Kinase; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Medication Adherence; Middle Aged; Muscular Diseases; Prevalence; Retrospective StudiesCreatine KinaseDyslipidemiasRetrospective Studiesbusiness.industryRetrospective cohort studyOdds ratioOriginal ArticlesMiddle AgedConfidence intervalDiscontinuation030104 developmental biologyItalyConcomitantCohortadverse effectsOriginal ArticleFemaleHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessstatin-associated muscle symptommyopathyJournal of Internal Medicine
researchProduct

Short-term Changes in Gal 3 Circulating Levels After Acute Myocardial Infarction.

2016

Background and Aims Galectin 3 (Gal 3) is a β-galactoside-binding lectin known to play a part in inflammation, adverse remodeling and fibrosis. Gal 3 seems to be linked to atherogenesis and Coronary Artery Disease (CAD), but less is known about the relationship between Gal 3 and acute myocardial infarction (AMI). The aim of the present study is to assess circulating levels of Gal 3 after AMI and to evaluate short-term changes of the biomarker within 5 days from the acute event. Methods Two hundred fifteen confirmed AMI patients (125 STEMI, M/F = 2.8; mean age: 65.4 ± 13.8 years) were enrolled in the present study; two blood samples were collected from each patient: first, within 1 h from ad…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsGalectin 3Myocardial InfarctionInflammationCoronary Artery Disease030204 cardiovascular system & hematologyAMICoronary artery disease03 medical and health sciences0302 clinical medicineFibrosisInternal medicineMedicineHumansCADcardiovascular diseasesMyocardial infarctionPlaqueAgedInflammationbusiness.industryMedicine (all)Mean ageGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyGalectin-3ImmunologyCardiologyBiomarker (medicine)Femalemedicine.symptombusinessBiomarkersArchives of medical research
researchProduct

Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Dif…

2018

AbstractAimsRelatively little is known about the health outcomes associated with very low plasma concentrations of high-density lipoprotein cholesterol (HDL-C) mainly because of the small numbers of individuals with such extreme values included in clinical trials. We, therefore, investigated the association between low and very low HDL-C concentration at baseline and incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical And Racial Differences in Stroke (REGARDS) study.Methods and resultsAnalysis was based on 21 751 participants from the REGARDS study who wer…

0301 basic medicineMalemedicine.medical_specialtyTime FactorsPhysiologyDown-RegulationCoronary Disease030204 cardiovascular system & hematologyRisk AssessmentWhite People03 medical and health sciences0302 clinical medicineSex FactorsRisk FactorsPhysiology (medical)Internal medicineCause of DeathNeoplasmsmedicineHumansLongitudinal StudiesStrokeCause of deathAgedDyslipidemiasCancer Death Ratebusiness.industryProportional hazards modelIncidence (epidemiology)IncidenceHazard ratioCholesterol HDLHealth Status DisparitiesMiddle AgedProtective Factorsmedicine.diseaseConfidence intervalUnited StatesResidual riskBlack or African AmericanStroke030104 developmental biologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular research
researchProduct

Endothelial GLP-1 (Glucagon-Like Peptide 1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension

2019

Supplemental Digital Content is available in the text.

0301 basic medicineMalemedicine.medical_specialtyhypertensionBlotting WesternInflammationBlood Pressure030204 cardiovascular system & hematologyangiotensin IImedicine.disease_causeGlucagon-Like Peptide-1 Receptor1005403 medical and health sciencesMice0302 clinical medicine10030Internal medicinemedicineoxidative stressAnimalsHypoglycemic AgentsReceptor10111Cells CulturedMice KnockoutliraglutideLiraglutidebusiness.industryBasic SciencesType 2 Diabetes MellitusEndothelial CellsAtherosclerosisGlucagon-like peptide-1Angiotensin II3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinology10040inflammationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGRNAmedicine.symptomCardiology and Cardiovascular Medicinebusiness10024Oxidative stressmedicine.drug
researchProduct

Low Dietary Magnesium and Overweight/Obesity in a Mediterranean Population: A Detrimental Synergy for the Development of Hypertension. The SUN Project

2020

Hypertension is the strongest independent modifiable risk factor for cardiovascular disease. We aimed to investigate the association of magnesium intake with incident hypertension in a Mediterranean population, and the potential modification of this association by body mass index BMI. We assessed 14,057 participants of the SUN (Seguimiento Universidad de Navarra) prospective cohort (67.0% women) initially free of hypertension. At baseline, a validated 136-item food frequency questionnaire was administered. We used Cox models adjusted for multiple socio-demographic, anthropometric, and lifestyle factors, and prevalent conditions present at baseline. Among a mean 9.6 years of follow-up we obs…

0301 basic medicineMaleobesitySettore MED/09 - Medicina InternaMediterranean diet030204 cardiovascular system & hematologyOverweightmagnesiumDiet Mediterranean0302 clinical medicinecohort studiesRisk FactorsMagnesiumLongitudinal StudiesProspective StudiesUncategorizededucation.field_of_studyNutrition and DieteticsIncidenceMiddle AgedCohortHypertensionCohort studiesFemalemedicine.symptomlcsh:Nutrition. Foods and food supplyCohort studyAdulthypertensionPopulationlcsh:TX341-641Diet SurveysArticle03 medical and health sciencesYoung AdultEnvironmental healthmedicineHumansoverweightObesityRisk factoreducation030109 nutrition & dieteticsbusiness.industryFeeding BehaviorOverweightmedicine.diseaseObesityDietSpainSelf ReportbusinessdietBody mass indexFood ScienceFollow-Up StudiesNutrients
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Native Mitral Valve Endocarditis Caused by Neisseria elongata subsp. nitroreducens in a Patient with Marfan Syndrome: First Case in Italy and Review …

2016

Neisseria elongata(NE) is an aerobic Gram-negative organism that constitutes part of the commensal human normal oropharyngeal flora. Although previously considered not to be pathogenic, it has been recognized as an occasional cause of significant infections in humans. We report here the first case in Italy of infective endocarditis of a native prolapsing mitral valve in a patient with Marfan syndrome, caused by NE subspeciesnitroreducenswhich has been rarely isolated from clinical specimens. The culprit organism has been confirmed by mass spectrometry directly from the positive blood culture, as previously reported. The amplified gene has been deposited in GenBank under accession number KT5…

0301 basic medicineMarfan syndromePathologymedicine.medical_specialty030106 microbiologyCase Report030204 cardiovascular system & hematologyMicrobiologylcsh:Infectious and parasitic diseases03 medical and health sciencesMitral valve endocarditis0302 clinical medicineMitral valveMedicineEndocarditislcsh:RC109-216Neisseria elongata subsp nitroreducensNeisseria elongatabiologybusiness.industryGeneral MedicineNeisseria elongatabiology.organism_classificationmedicine.diseasemedicine.anatomical_structureInfective endocarditisPositive blood cultureendocarditisbusinessCase Reports in Infectious Diseases
researchProduct

Ranolazine-Mediated Attenuation of Mechanoelectric Feedback in Atrial Myocyte Monolayers.

2020

[EN] Background Mechanical stretch increases Na(+)inflow into myocytes, related to mechanisms including stretch-activated channels or Na+/H(+)exchanger activation, involving Ca(2+)increase that leads to changes in electrophysiological properties favoring arrhythmia induction. Ranolazine is an antianginal drug with confirmed beneficial effects against cardiac arrhythmias associated with the augmentation ofI(NaL)current and Ca(2+)overload. Objective This study investigates the effects of mechanical stretch on activation patterns in atrial cell monolayers and its pharmacological response to ranolazine. Methods Confluent HL-1 cells were cultured in silicone membrane plates and were stretched to…

0301 basic medicineMechanical stretchOptical mappingMechanoelectric feedbackPhysiologyRanolazine030204 cardiovascular system & hematologyFibrillatory patternslcsh:PhysiologyTECNOLOGIA ELECTRONICA03 medical and health sciences0302 clinical medicineRanolazinePhysiology (medical)Optical mappingMonolayermechanoelectric feedbackmedicineMyocyterotor dynamic analysisAtrial myocytesranolazineOriginal ResearchFibrillationHL-1 celllcsh:QP1-981ChemistryAttenuationmechanical stretchElectrophysiologyRotor dynamic analysisoptical mapping030104 developmental biologyfibrillatory patternsBiophysicsmedicine.symptommedicine.drugFrontiers in physiology
researchProduct